Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding Div RTS (OP:RHHVF)

471.27 -7.39 (-1.54%)
Streaming Delayed Price Updated: 1:01 PM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Roche Holding Div RTS

< Previous 1 2 3 4 5 6 Next >
News headline image
Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M ↗
Friday, LumiraDx Limited (NASDAQ: LMDX) appointed joint administrators for two subsidiaries. 
Via Benzinga
News headline image
Poseida Therapeutics' New Treatment For Multiple Myeloma Shows Early Success In Clinical Trial ↗
Poseida Therapeutics Inc (NASDAQ: PSTX) released early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen... 
Via Benzinga
News headline image
Roche's Combination Therapy Shows Improved Progression Free Survival In Certain Breast Cancer With Mutation ↗
Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance) and fulvestrant as a potenti 
Via Benzinga
News headline image
Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs ↗
Roche Holding AG (OTC: RHHBY) has agreed to 
Via Benzinga
News headline image
Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks ↗
Sarepta Therapeutics Inc (NASDAQ: SRPT) released topline results from EMBARK (Study SRP-9001-301) Phase 3 study of Elevidys (delandistrogene moxeparvovec-rokl) in ambulatory boys (those who can walk)... 
Via Benzinga
News headline image
Roche Reports Nine Months Sales Growth Despite Lower Sales From COVID-19 Products ↗
Roche Holdings AG's (OTC: RHHBY) nine months  
Via Benzinga
News headline image
What's Going On Cancer Player Monte Rosa Therapeutics Stock Today? ↗
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) entered into a strategic collaboration and licensing agreement with Roche Holdings AG (OTC:  
Via Benzinga
News headline image
Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready ↗
Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool. While several blood tests for Alzheimer's diagnosis are... 
Via Benzinga
News headline image
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges ↗
Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY 
Via Benzinga
News headline image
Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year ↗
In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday. 
Via Benzinga
News headline image
Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope ↗
Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for hypertension,  
Via Benzinga
News headline image
Roche's Approved Lung Cancer Drug Beats Chemo In Rare Type Of Lung Cancer ↗
Roche Holdings AG (OTC: RHHBY) announced that the Phase 3 ALINA study evaluating Alecensa (alectinib), compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival (DFS)... 
Via Benzinga
News headline image
Cancer Treatment In 7 Minutes: UK's Health Service To Rollout Roche's Tencentriq Injection Cutting Treatment Time ↗
The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval to the National Health Service (NHS) to impleme 
Via Benzinga
News headline image
Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update ↗
Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus... 
Via Benzinga
News headline image
Roche's Accidental Lung Cancer Trial Data Leak: Shows Encouraging Early Data From Combination Therapy Study ↗
Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of t 
Via Benzinga
News headline image
Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients ↗
Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs 
Via Benzinga
News headline image
Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations ↗
Cancer drug manufacturers, including Johnson & Johnson (NYSE: JNJ), anticipate that injectable versions of some popular treatments will not be included in U.S. 
Via Benzinga
News headline image
Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List ↗
The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen 
Via Benzinga
News headline image
Alnylam Inks Co-Development, Co-Commercialization Pact With Roche For Hypertension Therapy ↗
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) entered a strategic agreement with Roche Holdings AG (OTC: RHHBY) to  
Via Benzinga
News headline image
Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal ↗
Roivant Sciences Ltd (NASDAQ: ROIV), a biotech company founded by Vivek Ramaswamy, a Republican presidential candidate, is reportedly in discussions with Roche Holdings AG (OTC: RHHBY) 
Via Benzinga
News headline image
Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion ↗
Roche Holdings AG's (OTC: RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with... 
Via Benzinga
News headline image
Roche's Bispecific Antibody With Fixed-Duration Treatment Scores FDA Approval For Type Of Lymphoma ↗
The FDA approved Roche Holding AG's (OTC: RHHBY) Columvi (glofitamab-gxbm) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma (LBCL)... 
Via Benzinga
News headline image
New Data Show Roche's Self-Administered Blood Disorder Candidate Achieves Disease Control ↗
Roche Group Holdings AG's (OTC: RHHBY) data from the global phase 3 COMMODORE 1 and 2 studies e 
Via Benzinga
News headline image
Roche's Investigational Drug For Relapsing Multiple Sclerosis Reduces Brain Lesions, Data Shows ↗
Roche Holdings AG's  (OTC: RHHBY) Phase 2 FENopta study of oral fenebrutinib for relapsing forms of multiple sclerosis (RMS)  
Via Benzinga
News headline image
Roche's Q1 Highlights: Increased Uptake Of Eye Disease Drug Cushions Sales Decline ↗
Roche Holdings AG's (OTC: RHHBY) first-quarter sales dropped 7% Y/Y (down 3% at constant currency)  
Via Benzinga
News headline image
FDA Approves Roche's Polivy Combo Therapy For Untreated Patients With Diffuse Large B-Cell Lymphoma ↗
 
Via Benzinga
News headline image
EXCLUSIVE: FDA Grants Expedited Review Status To SAB Biotherapeutics' Influenza Antibody ↗
The FDA has granted Fast Track designation for SAB Biotherapeutics' (NASDAQ: SABS) SAB-176, an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those... 
Via Benzinga
News headline image
New Four Year Data For Roche's Evrysdi Reinforces Long-Term Efficacy, Safety Profile In Muscular Atrophy Patients ↗
 
Via Benzinga
News headline image
FDA Casts Doubts Over Roche's Polivy Label Expansion For Untreated Lymphoma Setting ↗
 
Via Benzinga
News headline image
Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.